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The  production  of IgG  by  B  cells  is  regulated  by  another  population  of 
lymphocytes called T cells (1, 2). Different subpopulations of T cells serve to help 
(Th cells) or to suppress  (Ts cells) IgG production (3-5). A striking example of 
the latter is neonatally induced Ts cells that suppress production of the paternal 
IgG2a allotype in (BALB/c ~  × SJL d)Ft mice (6). The reported mode of action 
for these Ts cells is that they remove or inactivate allotype-specific Th cells, i.e., 
B  cells default in their production of the paternal  IgG2a allotype for lack of 
specific Th cells (5). We have evidence for another mode by which T cells may 
prevent IgG2a allotype production:  in  this,  the  B  cell  is  the direct target  of 
allotype-specific T cells. 
Using adult Ig-congenic strains  of BALB/c mice, we recently were able to 
demonstrate cytotoxic or suppressor T cells (Tcs) which are specific for the IgG2a 
allotype of C57BL mice (G  2) (7). In the appropriate host, these G 2 Tcs cells stop 
the normal production of IgGza allotype but not that of IgG1 or IgG2b allotype. 
We now show that G  2 Tcs cells are also able to prevent the growth of a congenic, 
G~-producing plasmacytoma (CBPC 101). This is interpreted as direct evidence 
for  allotype-specific interaction  between  T  and  B  lymphocytes; the  possible 
significance of such cell-cell interaction for IgG regulation is discussed. 
Materials and Methods 
Mouse Stratns and Allotypes.  The strains of mice that relate to this study include BALB/c and 
three Ig-congemc partner strains, C B-17, C B-20, and C.AL-20. The manner m  which these mice 
were bred is reported elsewhere (8,  9)  C B  and C AL refer to BALB/c mine that carry the Ig 
allotypes of the C57BL/Ka and AL/N mouse strains, respectively; the number after the hyphen 
(e.g,  C.AL-20)  indicates how many retrogressive backcrosses preceded the demvatmn of each 
strain 
IgG2a allotypes of BALB/c (G  1. ~ 7 s), C.AL (G  4 '~  7 s), and C.B (G  z) mice are denoted with the 
Potter-Lieberman nomenclature (8).  The IgG2a allotype of C57BL (G2), whmh is not known to be 
different from that of SJL mice, is alternately denoted Ig-lb by Herzenberg et al.  (5, 6). 
CBPC 101 Plasmacytoma  CBPC 101, a  G2-producing B-cell tumor, was induced in a  C.B-20 
mouse by Dr  Mmhael Potter. We received this tumor in its fifth transplant generation, and for 
these expemments we semally transferred CBPC 101 ascites mtrapemtoneally m  C.B-17 mice. 
Cell Transfers  Cell counts of spleen cells and CBPC 101 tumor cells were made in a hemocy- 
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tometer and the number of viable cells scored on the basis of their ability to exclude eosin. In some 
expemments, cells were  exposed to AKR mouse antl-Thy 1.2 serum (from Dr  J  B  Smith) and 
complement; control cell suspensions received the same treatment except that AKR normal serum 
was substituted for AKR antl-Thy 1.2 serum  This was done as described previously (7)  All cell 
preparations were made up in Hanks' balanced salt solution containing 2% fetal calf serum (Flow 
Laboratories,  Inc,  Rockvllle,  Md.)  and  were  rejected  intrapemtoneally  m  0.5-1.0-ml  vol  per 
mouse 
The  sublethal  X-irradiation  of BALB/c  recipients  (550  R)  was  carried  out  1  day  before  cell 
transfer at the following conditions' 190 kV'15 mA; filtration 1 mm Al and 0.5 mm Cu; dose rate 40- 
45 R  mln-'. At various times after cell transfer, recipients were bled and their sera reacted with 
BALB/c antl-G  2 m  mlcro-Ouchterlony plates to test for the presence of the G 2 marker 
Results and Discussion 
G2-specific  immunity of normal  mice  was  first  inferred from the  relative 
inability of CBPC  101  to grow in BALB/c and in C.AL-20 mice.  As shown in 
Table I, intraperitoneal injections of CBPC 101  cells (5  ×  106) into BALB/c or 
C.AL-20 mice did not result in a tumor, except in 2 of 50 mice injected (groups A- 
C). When tumor cells of the same preparation as used in groups A and C were 
given to C.B-17 mice, all recipients died with the tumor 3-7 wk later (group D). 
The  significance  of these  results  is  noted  by  the  fact  that  the  CBPC  101 
plasmacytoma was induced in a  C.B-20  mouse and that mice of the BALB/c, 
C.AL-20, and C.B-17 (or C.B-20) strains are known to differ from each other only 
with respect to Ig allotypes. Thus, C.B-17  mice are apparently tolerant to the 
growth of CBPC  101  because their IgG2a allotype is the same as that of the 
tumor, whereas BALB/c and C.AL-20 mice have different IgG2a allotypes and 
resist the growth of CBPC 101 cells. 
None of the mice in groups A-C of Table I produced detectable anti-G  2. This 
suggested to us that the tumor elicited a  cellular immune response in which 
allotype-specific T cells were the mediators. To test this idea, we carried out the 
experiments shown in Table II. Here, we used sublethally X-irradiated (550 R) 
BALB/c mice as recipients of various cell mixtures containing CBPC 101 cells. 
X-irradiation before the injection of CBPC 101 cells enabled the tumor to grow as 
indicated by the production of G  2 (group A). Further, all of these recipients died 
of the tumor within 5 wk.  However, as indicated in group B,  CBPC  101  cells 
would not grow and produce G  2 when cotransferred with BALB/c spleen cells 
taken from donors that received CBPC 101 cells 15 wk earlier (from group A of 
Table I). When the same spleen cell suspension was treated with AKR anti-Thy 
1.2 serum and complement (instead of with normal AKR serum and complement 
as in group B), the tumor did grow (group B'). Thus, it seems clear that spleen 
cells  from  CBPC  101-challenged  mice  contain  T  cells  that  can  prevent  the 
growth of the tumor. It is important to note that we did not obtain any evidence 
for suppressed tumor cells in the spleens of CBPC  101-challenged mice as the 
transfer  of anti-Thy  1.2-treated  spleen  cells  alone  did  not  result  in  any  G  2 
production or obvious tumor growth (group B"). Presumably, suppressed tumor 
cells would have become active in the absence of suppressor T cells. Thus, the 
likely fate of CBPC 101 cells m  BALB/c mice is death from lysis or from a T-cell 
factor. 
Table  II  demonstrates  further  that  spleen  cells  of  CBPC  101-challenged 
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TABLE  I 
Allotype-Dependent Immunity of Ig-Congenic BALB/c Mice to CBPC 101  Tumor Cells 
Group  Recipients* 
No  mlce hying/no  Injected  (weeks after  tumor injectmn) 
1  3  5  7  9  15 
A  BALB/c  9/9  9/9  9/9  9/9 
B  BALB/c  28/28  28/28  27/28  26/28 
C  C AL-20  13/13  13/13  13/13  13/13 
D  C B-17  9/9  5/9  1/9  0/9 
* Each recipient was rejected intraperltoneally with 5 x  10  6 CBPC 1Ol cells 
TABLE  II 
Evidence that BALB/c Immunity to CBPC 101  is Mediated by G 2 Tcs Cells* 
Group 
Cotransfer of  cells  into  X-lrradmted BALB/c re- 
clplents 
No reclplentsshowlngCJ/no  mJectedsurvlvors  (weeks  after 
cell  transfer) 
Spleen cells  CJ target  cells  I  2  3  5  7 
A  CBPC  101  5/6  2/2  i/I  All dead 
B  BALB/c challenged  CBPC  101  3/6  0/6  0/6  0/6  0/6 
with CBPC 101 
B'  (Anh-Thy 1 2 treated)  CBPC 101  4/6  4/5  4/5  All dead 
B"  (Antl-Thy 1 2 treated)  0/6  0/6  0/6  0/6  0/6 
C  BALB/c challenged  C B-17 spleen  0/8  0/8  0/8  0/8  0/8 
with CBPC 101 
D  BALB/c normal  C B-17 spleen  0/6  5/6  6/6  6/6  6/6 
* 107 BALB/c spleen cells  were admixed wlth 2 x 106 CBPC  I01 cells  or 2 x I~ C B-17 spleen cells,  the mixture was injected 
mtraperltoneally m  X-irradlated BALB/c mice (550  R), X-irradlatlon  alone dld not cause any of  15 control  mlce to dle in the 
following  7  wk (not  shown)  Immune spleen  cells  were taken  from mice  challenged with  CBPC 101  cells  15  wk earlier  (from group 
A of  Table  I) Spleen cells  in  groups B' and B  ~  were  treated  with  AKR antl-Thy i 2  and  complement before  being  transferred  to  X- 
irra&ated BALB/c reclplents,  the spleen  cells  of  group B were  treated  m the  same manner except  that normal AKR  mouse serum 
was  substituted  for  AKR  antl-Thy i 2 Although not shown, the reclpmnts of  group  C still  continued to  produce the IgG~ anotype 
(F  ~)  of  C B-17 mice 7 wk after  cell  transfer  as evldent from reacting their  sera with anti-C~F' sera (7) 
This is shown in group C.  But as with G2-suppressed  C.B-17  mice in earlier 
experiments (7), the C.B-17 B cells in group C did not stop producing their IgG1 
allotype (F  s) (see footnote of Table II). Two conclusions can be drawn from these 
results. First, that CBPC 101 cells do not elicit BALB/c T cells which recognize a 
non-Ig determinant on all C.B-17 lymphocytes, such as a minor histocompatibil- 
ity antigen; otherwise, we would expect other C.B-17  allotype markers besides 
C_J (e.g., F s) to be suppressed also. Second, that T-cell immunity to CBPC 101 
must be directed against allotype determinants, i.e., we are not dealing with 
idiotypic determinants unique to the IgG2a molecules produced by CBPC  101 
since spleen cells from CBPC 101-challenged mice could suppress the G  2 produc- 
tion of normal C.B-17 B cells. Apparently, G  2  Tcs cells are responsible for BALB/ 
c immunity to CBPC 101. 
Evidence that G2-bearing B cells are the target of G  2 Tcs cells is presented in 
Table III. As shown in group A, the treatment of tumor cells with anti-Thy 1.2 
serum and complement to remove any associated T cells that might derive from 
the tumor-bearing C.B-17 host did not prevent the CBPC 101 cells from rapidly 
growing in X-irradiated BALB/c. Therefore, CBPC 101 B cells must not require 
the presence of specific Th cells (e.g.,  G  2 Th cells) in order to grow.  Thus, to 
prevent tumor growth, G  2  Tcs cells must recognize CBPC 101 B cells directly and 
presumably normal G2-producing B cells as well. Further, this recognition must 
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T~SLE III 
Prevention of CBPC 101  Tumor Growth by G 2 Tcs Cells: Suggested Presence of G 2 Tcs 
Cells tn Normal BALB/c Mice 
Group 
Cotransfer of  ceils  into  X-irradlated 
BALB/c reclplents 
No  reclplents  showlng GZ/no  rejected  survlvors (weeks after  cell 
transfer) 
Spleen cells  CBPC  101 cells  1  2  3  4  7  15 
A*  CBPC  101  6/6  3/3  I/1  All dead 
(2  ×  10  ~) 
B*  BALB/c antl-G  s  CBPC  101  0/6  0/6  0/6  0/6  0/6 
(10  7)  (2  x  10  6) 
C*  BALB/c  antl-G  4  CBPC  101  0/6  4/6  4/6  2/2  All dead 
(lO'q  (2  ×  10  ~) 
D  BALB/c normal  CBPC  101  0/12  0/12  0/12  2/12  2/12 
(2  ×  107)  (10  ~) 
E  C  B-17 normal  CBPC  101  0/12  7/12  5/5  2/2  All dead 
12  ×  10  ~)  {10 ~) 
0/10 
,  z  Immune spleen cells were taken from mice that were producing anh-G  m  response  to pumfied Fc fragments of C57BL/6 7S Ig (7) 
and from mice that were producing anh-G 4 (antl-C  AL-20 IgG2a)  The CBPC 101 cells m  groups A-C were treated  with AKR anh- 
Thy 1 2 serum and complement  before being transferred  into X-irradiated  BALB/c reclpmnts 
where CBPC 101  cells would not grow in the presence of BALB/c spleen cells 
containing G  z Tcs that had been primed against purified Fc fragments of C57BL 
7S Ig, whereas the tumor did grow in the presence of BALB/c spleen cells taken 
from mice immune to the IgG2a allotype of C.AL-20 mice (G4). 
Consistent with the results of  Table I, Table III also shows that normal BALB/ 
c (but not C.B-17)  spleen cells can prevent the growth of CBPC 101 tumor cells. 
Cotransferring BALB/c spleen  and CBPC  101  cells at  a  ratio of 20:1 into X- 
irradiated BALB/c mice resulted in only 2 of 12 recipients showing G2; both of 
these  animals  died  of large  tumors  (group  D).  Studies  are  in  progress  to 
determine whether normal G2-producing B cells (G  z antibody-forming  cells) can 
elicit a similar response of BALB/c spleen cells, i.e., the prevention of normal G  2 
production. 
The question prompted by the above results is how can spleen cells of normal 
BALB/c mice mount so rapid and effective a response against tumor cells that 
bear an allotype antigen that these mice have never seen experimentally? To 
account for this, we suggest that not only is the G  2 marker very antigenic, but 
that a  considerable number of G  2 Tcs cells or their precursors are present in 
normal BALB/c mice. In addition to the suggested presence of G  2 Tcs cells, we 
have unpublished evidence that BALB/c mice also contain Tcs cells directed 
against IgG2a allotype determinants (G  4) of C.AL-20 mice. This raises an inter- 
esting possibility that different mouse strains may contain different allotype- 
specific Tcs cells, and that the stimulus for generating such Tcs cells may be 
provided by allotype antigens normally undetectable (hidden allotypes). Irregu- 
larities or  specific stress of this regulatory system could result in detectable 
production of hidden allotypes. In fact, similar to our earlier findings (9), we can 
now show with radioimmune techniques the transient appearance of allotypes 
indistinguishable from those of BALB/c IgGl and IgG2a in C.B-17  mice. 1 Addi- 
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tional evidence for the regulatory control of allotype production is the observed 
nonallelic behavior of Ig allotypes in rabbits  (10,  11). Also,  the production  of 
unexpected  allotypes by normal  (and  neoplastic,  12) human  lymphocytes has 
been reported (13,  14); however, several laboratories (15,  16) have not been able 
to confirm these observations (13,  14). Structural  evidence consistent with the 
idea of regulatory control of allotype production is also available. Most constant 
region (C) allotypes of human heavy (H) chains correspond to multiple antigenic 
differences  (16),  some  of which  (in  the  case  of IgG3)  have  been  localized  to 
different CH regions (17). Moreover, constant region allotypes of light chains (CL) 
in rat (18) and in rabbit (19, 20), as well as rabbit allotypes on H chain variable 
regions (VH) (16), correlate not with a few but with many amino acid differences. 
Evolutionary considerations of such "complex" allotypes have led some (18-21) 
to  suggest that  these  allelic  differences may reflect the  products  of different 
linked genes and that the basis for the genetic polymorphism is in the control of 
such genes. 
The advantage of regulating  IgG production by allotype-specific Tcs cells is 
not clear although  one could suppose in the above context that  hidden mouse 
allotypes reflect CH allotype genes that are associated with different sets of VH 
genes; this, then, would suggest a way of controlling the expression of select sets 
of V~ genes. 
Summary 
BALB/c  T  cells,  which  can  prevent  normal  C57BL  IgG~  allotype  (G  a) 
production of Ig-congenic partner  mice  (C.B mice),  are shown capable of pre- 
venting the growth and G  a production ofa C.B plasmacytoma (CBPC 101). Such 
cytotoxic or suppressor T  cells are clearly allotype-specific (G  2 Tcs cells).  And 
since CBPC 101 B cells do not require specific helper T cells in order to grow, we 
infer that G2-bearing B cells (normal or neoplastic) must be the direct target of 
G  a Tcs cells. This mode of T cell prevention of allotype production contrasts that 
reported for suppressor T cells in (BALB/c ×  SJL)FI mice. 
We thank Dr. M. Potter for C.AL-20 mice and for the CBPC 101 myeloma, Dr. J. B  Smith for anti- 
thy 1.2 sera, and Mrs  Eva Cunningham for technical assistance. 
Note Added in Proof.  Our experiments do not exclude the possibility that in 
addition to G ~ determinants,  G 2 Tcs cells could recognize another determinant 
specific for G~-producing B cells. 
Received for publication 3 November 1976. 
References 
1.  MSller, G. 1969. Transplantation  reviews, vol. 1. Williams and Wilkins Co., Balti- 
more. 
2.  Gershon,  R. K. 1974. T cell control of antibody production.  Contemp.  Top. Immuno- 
biol. 3:1. 
3.  Cantor, H., and E. A. Boyse. 1975. Functional subclasses of T lymphocytes bearing 
different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a 
differentiative process independent of antigen. J. Exp. Med.  141:1376. 748  BOSMA  AND  BOSMA  BRIEF  DEFINITIVE  REPORT 
4.  Cantor,  H., and E. A. Boyse. 1975. Functional subclasses of T lymphocytes bearing 
different Ly antigens. II. Cooperation between subclasses of Ly  ÷ cells in the genera- 
tion of killer activity. J. Exp. Med.  141:1390. 
5.  Herzenberg, L. A., K. Okumura, H. Cantor, V. L. Sato, F. W. Shen, E. A. Boyse, and 
L.  A.  Herzenberg  1976. T-cell regulation of antibody responses' demonstration of 
allotype-specific helper T cells and the specific removal by suppressor T cells. J  Exp. 
Med.  144:330. 
6.  Herzenberg, L. A., E. L. Chan, M. M. Ravitch, R. S. Riblet, and L. A. Herzenberg. 
1973. Active suppression of immunoglobulin allotype synthesis. III. Identification of 
T cells as responsible for suppression by cells from spleen, thymus, lymph node, and 
bone marrow. J. Exp. Med.  137:1311. 
7  Bosma,  M.  J.,  and  G.  C  Bosma.  1976. Chronic  suppression  of immunoglobuhn 
allotype production in adult congemc mice. Nature (Lond.). 259:313. 
8.  Potter,  M.,  and R.  Lieberman.  1967. Genetic studies of immunoglobulins in mice. 
Cold Spring Harbor Syrup. Quant. Biol. 32:187. 
9.  Bosma, M. J., and G. C. Bosma. 1974. Congenic mouse strains: the expression of a 
hidden  immunoglobulin allotype in  a  congenic partner strain  of BALB/c mice. J. 
Exp. Med.  139:512. 
10  Strosberg, A.  D.,  C.  Hamers-Casterman, W.  van der Loo, and R. Hamers.  1974  A 
rabbit with the allotypic phenotype: ala2a3 b4b5b6.  J. Immunol.  113:1313. 
11.  Mudgett,  M.,  B.  A.  Fraser,  and T.  J.  Kindt  1975. Non-allelic behavior of rabbit 
variable-region allotypes. J. Exp. Med.  141:1448. 
12.  Pothier, L., H. Borel, and R. A. Adams. 1974. Expression of IgG allotypes m human 
lymphoid tumor lines serially transplantable  m  the  neonatal  Syrian hamster.  J. 
Immunol.  113:1984 
13.  Lobb, N. 1968. The synthesis ofimmunoglobulinTGby cultured human lymphocytes. 
Aust. J. Exp. Bml. Med. Sci. 46:397. 
14.  Rivat, L., D. Gilbert, and C. Ropartz. 1973. Immunoglobulin allotypm specificities in 
mixed leucocyte cultures. Immunology. 24:1041. 
15.  Litwin, S. D., T. H. Hiitteroth, and L. Balaban. 1976. Synthesis of Gin allotypes by 
human  tonsillar  lymphocytes in  culture:  concordance  with  serum  phenotype.  J 
Immunol.  116:1045. 
16.  Kunkel, H  G., and T. Kindt. 1975. Allotypes and ldiotypes. In Immunogenetics and 
Immunodeficiency. B.  Benacerraf, editor. University Park Press, Baltimore. 56. 
17.  Natvig, J. B., and H. G. Kunkel. 1968. Genetic markers of human lmmunoglobulins: 
Gm and Inv systems. Ser  Haematol.  1:66. 
18.  Gutman, G., E. Loh, and L.  Hood. 1975. Structure and regulation of lmmunoglobu- 
lins: kappa allotypes in the rat have multiple amino-acid differences m the constant 
region. Proc. Natl. Acad. Sci.  U  S. A. 72:5046 
19.  Farnsworth,  V.,  R.  Goodfliesh,  S  Rodkey,  and  L.  Hood.  1976  Immunoglobulin 
allotypes of rabbit kappa chains: polymorphism of a control mechanism regulating 
closely-linked duplicated genes? Proc.  Natl  Acad. Sc~  U. S. A.  73:1293. 
20  Strosberg,  A  D  1976. A  possible control  by regulatory  allelic  genes of allotypic 
expression. B~ochem.  Soc. Trans. 4:41. 
21.  Bodmer, W. F. 1973. A new genetic model for allelism at histocompatibility and other 
complex loci: polymorphmm for control of gene expression. Transplant  Proc. 4:1471. 